AU2006312119B2 - Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same - Google Patents

Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same Download PDF

Info

Publication number
AU2006312119B2
AU2006312119B2 AU2006312119A AU2006312119A AU2006312119B2 AU 2006312119 B2 AU2006312119 B2 AU 2006312119B2 AU 2006312119 A AU2006312119 A AU 2006312119A AU 2006312119 A AU2006312119 A AU 2006312119A AU 2006312119 B2 AU2006312119 B2 AU 2006312119B2
Authority
AU
Australia
Prior art keywords
formulation
ibuprofen
subject
cyclodextrin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006312119A
Other versions
AU2006312119A1 (en
Inventor
Toru Hibi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Pharma USA Inc
Original Assignee
Teikoku Pharma USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma USA Inc filed Critical Teikoku Pharma USA Inc
Publication of AU2006312119A1 publication Critical patent/AU2006312119A1/en
Application granted granted Critical
Publication of AU2006312119B2 publication Critical patent/AU2006312119B2/en
Priority to AU2010202050A priority Critical patent/AU2010202050A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Description

WO 2007/055887 PCT/US2006/041024 ORGANOLEPTICALLY ACCEPTABLE IBUPROFEN ORAL DOSAGE FORMULATIONS, METHODS OF MAKING AND USING THE SAME CROSS-REFERENCE TO RELATED APPLICATIONS 5 Pursuant to 35 U.S.C. § 119 (e), this application claims priority to the filing dates of: United States Provisional Patent Application Serial No. 60/733,127 filed November 2, 2005 and United States Provisional Patent Application Serial No. 60/810,417 filed on June 1, 2006; the disclosures of which are herein incorporated by reference. 10 INTRODUCTION Background of the Invention Sore throat, laryngitis, mouth and throat ulcers, excessive mucus and other mouth and throat irritations typically accompany common colds, influenza and like ailments. A variety of different medications, including medications available over 15 the-counter, have been developed to treat these types of maladies. Such medications include: Dyclonine lozenges (e.g., as sold under the trademark SUCRETSTM); benzocaine + menthol lozenges (e.g., as sold under the trademark CEPACOLTM); menthol lozenges (e.g., as sold under the trademark VICKS
TM
); and aspirin containing chewing gum (e.g., as sold under the trademark ASPERGUM
TM
). 20 ibuprofen (2-(p-isobutylphenyl)propionic acid) is a non-steroidal anti inflammatory agent (NSAID) which is known to possess analgesic and antipyretic activities. It is useful in the treatment of pain and inflammation associated with various maladies, including the common cold, toothaches, headaches, backaches, menstrual cramps (Dysmennorhea), the muscular aches and pains associated with 25 Premenstrual Syndrome, rheumatoid arthritis and osteoarthritis, as well as in the reduction of fever. As such, like other NSAIDs, ibuprofen has become widely used in prescription and over-the-counter formulations for the treatment of pain associated with inflammation, both minor and chronic. One of its drawbacks, however, is that 30 ibuprofen has an unpleasant, bitter taste which tends to limit its acceptability in many oral dosage forms. Methods of alleviating this limitation have included attempts at masking the bitter taste with flavored and/or sweetened mediums or by 1 WO 2007/055887 PCT/US2006/041024 coating the ibuprofen with substances which prevent it from contacting the taste buds during oral administration. For example, oral ibuprofen formulations currently available over the counter include suspensions of ibuprofen in oral sugar syrup containing formulations. 5 JP-4-26618 describes ibuprofen containing lozenges and their use in the treatment of sore throat. To overcome the bitterness of the ibuprofen active agent and thereby make the lozenge organoleptically acceptable, the disclosed lozenge formulations include a significant amount of cyclodextrin (e.g., at least twice as much cyclodextrin as ibuprofen) as a masking agent. 10 Because of the relatively expensive cost of cyclodextrin, there is continued interest in the development of new organoleptically acceptable oral ibuprofen formulations, e.g., formulations in which cyclodextrin is present in smaller amounts than that taught in JP-4-26618, if at all. Relevant Literature 15 United States Patent Nos. 5,024,997; 5,055,461; 5,780,046; 6,166,083; 6,194,003; 6,517,870; and 6,616,083. Also of interest are Japanese Patent Publication Nos. Sho.62-298528 and Hei.4-26618. Other references of interest include: Breslin et al., Chem. Senses (2001) 26:55-65; Hahn, Int.J.Clin.Pharm.Res. VI(1) 81-86(1986); Schactel et al., Clin. Pharmacol. Ther. (1988) 44: 704-711; and 20 Wilson et al., Drugs made in Germany 38,No.3(1995). SUMMARY OF THE INVENTION Organoleptically acceptable solid oral dosage formulations of ibuprofen, and methods of making and using the same, are provided. A feature of the subject 25 formulations is that they include ibuprofen and a masking component. In certain embodiments, the masking component includes one or more of a cooling agent, an organic acid and a cyclodextrin. The subject invention finds use in a variety of applications. DETAILED DESCRIPTION 30 Organoleptically acceptable solid oral dosage formulations of ibuprofen, and methods of making and using the same, are provided. A feature of the subject formulations is that they include ibuprofen and a masking component. In certain embodiments, the masking component includes one or more of a cooling agent, an 2 WO 2007/055887 PCT/US2006/041024 organic acid and a cyclodextrin. The subject invention finds use in a variety of applications. Before the present invention is described in greater detail, it is to be understood that this invention is not limited to particular embodiments described, as 5 such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims. Where a range of values is provided, it is understood that each intervening 10 value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any 15 specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to 20 which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described. All publications and patents cited in this specification are herein incorporated 25 by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present 30 invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed. 3 WO 2007/055887 PCT/US2006/041024 It is noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of 5 such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with 10 the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible. As reviewed above, the present invention provides organoleptically acceptable ibuprofen oral solid dosage formulations, as well as methods for making 15 and using the same. In further describing representative embodiments of the invention in greater detail, the organoleptically acceptable formulations are reviewed first in greater detail, followed by a review of representative protocols for making the formulations and a review of representative applications in which the formulations find use. 20 ORGANOLEPTICALLY ACCEPTABLE IBUPROFEN ORAL SOLID DOSAGE FORMULATIONS As summarized above, the subject invention provides organoleptically acceptable ibuprofen oral solid dosage formulations. As the formulations are 25 organoleptically acceptable, they can contact the taste receptors of a recipient's mouth and be considered generally acceptable to the senses of the recipient, particularly to the sense of taste. More particularly, the organoleptically acceptable formulations of this invention are those solid oral formulations in which the unpleasant and bitter taste of ibuprofen is sufficiently masked. Specifically, when 30 using the evaluation protocol reported in the Experimental Section below, the unpleasant and bitter taste of ibuprofen is considered to be sufficiently masked if the composition scores a 1 or less, e.g., 0 or less, such as -1 or less, including -2. 4 WO 2007/055887 PCT/US2006/041024 In a general sense, the subject formulations are not limited to ibuprofen formulations, but instead may be viewed as propionic acid derivative formulations. Propionic acid derivatives are a well known class of analgesic compounds. As used herein propionic acid derivatives are understood to include, but are not limited to, 5 ibuprofen, naproxen, benoxaprofen, naproxen sodium, flurbiprofen, fenoprofen, fenbuprofen, ketoprofen, indoprofen, pirprofen, carpofen, oxaprofen, pranoprofen, microprofen, tioxaprofen, suproprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid. The structural formula is set forth in U.S. Pat. No. 4,923,898, hereby incorporated by reference. Propionic acid derivatives as defined herein are defined 10 as pharmaceutically acceptable analgesics/non-steroidal anti-inflammatory drugs having a free -CH(CH 3 )COOH or -CH 2
CH
2 COOH or a pharmaceutically acceptable salt group, such as -CH(CH 3 )COO-Na* or CH 2
CH
2 COO-Na*, which are typically attached directly or via a carbonyl functionality to an aromatic ring system. For convenience and ease of description, the present invention is described 15 herein, primarily in terms of ibuprofen formulation embodiments. As such, the subject formulations of these representative ibuprofen formulation embodiments include an effective amount of ibuprofen. Ibuprofen is a widely used, well known non-steroidal anti-inflammatory propionic acid derivative. Ibuprofen is chemically known as 2-(4-isobutylphenyl)-propionic acid. As used herein, ibuprofen is 20 understood to include 2-(4-isobutylphenyl)propionic acid as well as pharmaceutically acceptable salts thereof. Suitable ibuprofen salts include arginine, lysine, histidine, as well as other salts described in U.S. Pat. No. 4,279,926, 4,873,231, 5,424,075 and 5,510,385, the contents of which are incorporated by reference. It should be noted that the ibuprofen active agent may be present as a 25 racemic mixture or as a stereoisomer, e.g., as the S(+) or R(-) ibuprofen sterioisomers. The amount of ibuprofren present in the subject formulations may vary, so long as it is effective to acheive the intended purpose of the formulation, e.g., to provide sore throat pain relief to a subject in need thereof, as further reviewed 30 below. In representative embodiments, the amount of ibuprofen present in the formulation ranges from about 5 to about 600 mg, such as from about 20 to about 400 mg, including from about 50 to about 200 mg. 5 WO 2007/055887 PCT/US2006/041024 In addition to the ibuprofen active agent, the subject formulations also include a masking component. By masking component is meant a component that is made up of one or more agents which provides for sufficient masking of the ibuprofen bitterness to make the formulation organoleptically acceptable. In representative 5 embodiments, the masking component is made of one or or more of a cooling agent, an organic acid and a cycodextrin. In certain embodiments, the masking component includes two or more of a cooling agent, an organic acid and a cyclodextrin, including all three of a cooling agent, an organic acid and a cyclodextrin. 10 As such, certain embodiments of the subject invention include one or more cooling agents. By "cooling agent" is meant an agent that, when contacted with skin of a subject, imparts a cooling sensation or effect to the subject. Cooling agents can be selected from any of a wide variety of materials. Included among such materials are carboxamides, menthol, ketals, diols, and mixtures thereof. In certain 15 embodiments, the cooling agent is an acyclic amide, where representative acyclic amides include compounds of the formula: R1 R2-C*'-CONHR' R3 where 20 R 1 , R 2 and R 3 are each C 1
-C
5 alkyl and together provide a total of at least 5, such as from about 5-10 carbon atoms; and R' is C1 -C5 alkyl, C1 -C8 hydroxyalkyl or alkylcarboxyalkyl of up to 8 carbon atoms. In this group R 1 is in representative embodiments, methyl, ethyl or n-propyl and one or both of R 2 and R 3 is branched in an alpha or beta position relative to the carbon atom marked (*). In representative 25 embodiments, the cooling agent is N,2,3-trimethyl-2-isopropyl butamide (also known as WS-23; CAS # 51115-67-4). The above compounds can be produced using any convenient protocol, where representative protocols are described in U.S. Patent No. 4,296,255. Other representative cooling agents of interest include, but are not limited to: linalool, geraniol, hydroxycitronellal, cyclohexanecarboxamide, N-ethyl-5 6 WO 2007/055887 PCT/US2006/041024 metyhy-2-(1-methylethyl) (also known as WS-3; CAS # (39711-79-0), Flescolat MGA (Haarman & Reimer), Frescolat ML (Haarmann & Reimer), PMD38 (Takasago), CoolactP (Takasago) and Cooling Agent 10 (Takasago). Additional preferred cooling agents are selected from the group consisting of menthol, 3-1 5 menthoxypropane-1,2-diol known as TK-1 0 manufactured by Takasago; menthols and menthyls, where these as used herein include dextro- and levorotatory isomers of these compounds and racemic mixtures thereof. TK-10 is described in U.S. Pat. No. 4,459,425, Amano et al., issued Jul. 10, 1984. WS-3 and other agents are described in U.S. Pat. No. 4,136,163, Watson, et al., issued Jan. 23, 1979; the 10 disclosures of which are incorporated herein by reference, as well as various oils, such as peppermint oil, spearmint oil, and the like. The amount of cooling agent that is present in the formulation is an amount sufficient (e.g., by itself or in combination with other masking agents of the masking component) to mask or hide the bitterness of ibuprofen and thereby make the 15 formulation organoleptically acceptable. In representative embodiments, based on the ratio to ibuprofen, the amount ratio of cooling agent to ibuprofen present in the formulation ranges from about 0.25 to about 2,such as from about 0.5 to about 1.5,and including from about 0.5 to about 1. The masking component may also include one or more organic acids, 20 including amino acids. Organic acids of interest include, but are not limited to: glycolic acid, lactic acid, methyl lactic acid, palycarobxlyic acids, e.g., malic acid, citric acid, tartronic acid, tartaric acid, succinic acidetc. Amino acids of interest include, but are not limited to: glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, cystine, methionine, aspartic acid, asparagine, glutamic acid, 25 glutamine, arginine, lysine, 5-hydroxylysine, histidine, phenylalanine, tyrosine, tryptophan, 3-hydroxyproline, 4-hydroxyproline, proline, homocysteine, homocystine, homoserine, ornithine, citrulline, creatine, asparaginic acid, 3 aminopropanoic acid, theanine, 2-aminobutanoic acid, 4-aminobutanoic acid, 2 amino-2-methylpropanoic acid, 2-methyl-3-aminopropanoic acid, 2,6-diaminopimelic 30 acid, 2-amino-3-phenylbutanoic acid, phenylglycine, canavanine, canaline, 4 hydroxyarginine, 4-hydroxyornithine, homoarginine, 4-hydroxyhomoarginine, p lysine, 2,4-diaminobutanoic acid, 2,3-diaminopropanoic acid, 2-methylserine, 3 7 WO 2007/055887 PCT/US2006/041024 phenylserine betaine, sulfur-containing amino acids, such as taurine, cysteinesulfinic acid, methionine sulfoxide and methionine sulfone. The amount of organic acid (including amino.acid) masking agent that is present in the formulation is an amount sufficient (e.g., by itself or in combination 5 with other masking agents of the masking component) to mask or hide the bitterness of ibuprofen and thereby make the formulation organoleptically acceptable. In representative embodiments, based on the ratio to ibuprofen, the amount ratio of organic acid to ibuprofen present in the formulation ranges from about 0.5 to about 4,such as from about 1 to about 3,and including from about 1 to 10 about 2. In representative embodiments, the masking component includes a cyclodextrin. The cyclodextrin may be any convenient cyclodextrin or mixture of cyclodextrins, including a-, P- or y-cyclodextrins. In representative embodiments, cyclodextrin is P- cyclodextrin. A feature of embodiments of the invention is that, 15 when present, the total amount of cyclodextrin in a given formulation is less than twice the amount of ibuprofen active agent in the formulation, such as less than about 1.5 times the amount of ibuprofen active agent, including less than about 1 times the amount of ibuprofen active agent, in terms of mass. As summarized above, the subject formulations are orally acceptable solid 20 formulations. The solid formulations may be present in a number of different formats, where representative formats include, but are not limited to: lozenges, troches, tablets, liquid formulations such as gargles and sprays, and gums. The term "lozenge" as used herein is intended to embrace all dosage forms where the product is formed by cooling a sugar-based or sugar alcohol based (e.g., sorbitol) 25 molten mass containing the active material. The term "tablet" as used herein is intended to embrace unit dosage forms made from compressed powders or granules or compressed pastes. Solid dosage forms may be prepared by methods which are well known in the art for the production of lozenges, tablets, troches, capsules or chewing gums and may contain other ingredients known in such dosage 30 forms such as acidity regulators, opacifiers, stabilizing agents, buffering agents, flavorings, sweeteners, coloring agents, buffering agents, sweeteners and preservatives. 8 WO 2007/055887 PCT/US2006/041024 For example, solid formulations of the present invention may be prepared as lozenges by heating the lozenge base (e.g., a mixture of sugar and liquid glucose) under a vacuum to remove excess water. The remaining components are then blended into the mixture. The resulting mixture is then drawn into a continuous 5 cylindrical mass from which the individual lozenges are formed. The lozenges are then cooled, subjected to a visual check and packed into suitable packaging. One form of suitable packaging is a blister pack of a water-impermeable plastics material (e.g., polyvinylchloride) closed by a metallic e.g., aluminium foil. The patient removes the lozenge by applying pressure to the blister to force the lozenge to 10 rupture and pass through the metal foil seal. Lozenges will normally be sucked by the patient to release the ibuprofen. Where desired, ethanol can be used to dissolve ibuprofen, menthol, WS-23, and WS-3. As for preparation of a troche, a wet granulation method can be used generally to prepare granules for tabletting into a troche formulation. Ethanol can be 15 used to dissolve ibuprofen, menthol, WS-23, and WS-3, if necessary. After granulation, the wet granule is dried ,then mixed with lubricant ,and finally tabletted into a troche. Masticable solid dosage formulations may be made by the methods used to prepare chewable candy products or chewing gums. For example, a chewable solid 20 dosage form may be prepared from an extruded mixture of sugar syrup to which the ibuprofen has been added with optional addition of whipping agents, humectants, lubricants, flavors and colorings. (See Pharmaceutical Dosage Forms: Tablets, Volume 1, Second Edition edited by H A Lieberman, L Lachman and J B Schwartz published in 1989). 25 As such, a variety of different solid dosage formulations are provided by the subject invention. Furthermore, the solid dosage formulations do not need a special procedure for their preparation, as they may be readily produced using conventional procedures. For example, taste-masking agents, diluents, binders, or other appropriate additives can be added to ibuprofen, to which water or organic solvents 30 are added, if necessary, and then mixed evenly to be compacted or to be granulated, and then mixed with lubricant to be compacted. For a diluent, sugar is mainly used and one or more types of sugar such as white sugar, powder sugar, lactose, fructose, starch syrup, reduced malt sugar, D- mannitol, D-sorbitol, and 9 WO 2007/055887 PCT/US2006/041024 sucrose. For a binder, polyvinyl pyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, corn starch, gelatin and arabic gum are used. For a lubricant, magnesium stearate, talc, sucrose fatty acid ester and such are properly selected and used. 5 In many embodiments, the methods of manufacture may be characterized by including a first step of producing an intermediate composition, which composition includes the active agent and masking component, and then a second step of producing the oral dosage formulation from the intermediate composition. 10 METHODS OF USING SUBJECT FORMULATIONS The subject organoleptically acceptable ibuprofen solid oral dosage formulations find use in applications of delivering ibuprofen to a subject in need thereof, particularly to a laryngopharynx (e.g., throat) location of a subject. In 15 practicing the invention, the dosage may be placed in the mouth of the subject, e.g., by the subject itself or a caregiver therefore, whereupon the subject holds the formulation in its mouth to obtain the desired benefit, where the term holding is used broadly to include sucking, chewing, etc, depending on the particular type of formulation. In this manner, the direct action of ibuprofen dissolved in saliva or oral 20 cavity is exerted on mucosal membrane, e.g., for treatment of sore throat. In practicing the subject methods, a formulation may be administered a single time or a plurality of times over a given time period, e.g., the course of the disease condition, e.g., inflammation, being treated, where the dosing schedule when a plurality of formulations are administered over a given time period may be hourly, 25 daily etc. The above described formulations and methods find use in any application in which the administration of ibuprofen to a subject, particularly to a laryngopharynx location thereof, is desired. Among other applications, the subject methods as described herein are effective for treating inflammation, aches, etc., including the 30 maladies reviewed in the introduction section of this application, e.g., sore throat, hoarse voice, etc. Generally such subjects are "mammals" or "mammalian," where these terms are used broadly to describe organisms which are within the class mammalia, 10 WO 2007/055887 PCT/US2006/041024 including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In many embodiments, the hosts will be humans. In representative embodiments, the subject methods find use in the treatment 5 of a sore throat. In yet other embodiments, the subject methods find use in the treatment of hoarse voice, e.g., as may occur from extended periods of voice use, e,g., speaking, singing etc. By treatment is meant at least an amelioration of pain afflicting the host, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of pain. As such, treatment also includes situations 10 where the pain is completely inhibited, e.g. prevented from happening, or stopped, e.g. terminated, such that the host no longer suffers from the pain. As such, treatment includes both curing and managing a pain, e.g., of a sore throat. KITS 15 Also provided are kits, where the subject kits at least include one or more, e.g., a plurality of, organoleptically acceptable oral solid dosage formulations, as described above. The subject formulations in the kits may be present in a package. The formulations of the kits are typically present in individual pouches or analogous 20 containers, to preserve the composition of the formulations until use. The subject kits also generally include instructions for how to use the formulations, where the instructions typically include information about how to administer the formulation, dosing schedules etc. The instructions are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, 25 such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e. associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. 30 11 WO 2007/055887 PCT/US2006/041024 The following practical and comparative examples are offered by way of illustration and not by way of limitation. EXAMPLES 5 1. Working example I After 1.0 g of ibuprofen and 0.5 g of I-menthol were dissolved in 2 ml of EtOH, the resultant solution was added to 4g of D-sorbitol in a motor, and the resultant composition was kneaded well. After the composition was dried at room 10 temperature overnight, it was pulverized by motor, sieved with 0.5mm opening, and then mixed with 0.1g of Mg-st (magnesium stearate) for 10 seconds. The prepared granules were put into a molder for tabletting (13 mm in diameter, in 1.5-2.0t pressure for 20 secs.),to obtain 20 troches, each of which weighed 200 mg (36.4 mg of ibuprofen, 18.2 mg of I-menthol). 15 2. Working example 2 1.0 g of ibuprofen and 0.5 g of WS-23 (commercialized cooling compound; N,2,3-trimethyl-2-isopropyl butamide; from Millennium Specialty Chemicals) were dissolved in 2 ml of EtOH, and the resultant solution was added to 4 g of D-sorbitol 20 in a motor. The resultant composition was then kneaded well. Afterwards, the composition was dried at room temperature overnight, pulverized by motor and sieved with 0.5 mm opening. The resultant particles were then mixed with 0.1g of Mg-st(magnesium stearate) for 10 sec. The prepared granules were then put into a molder for tabletting (13 mm in diameter, in 1.5-2.Ot pressure for 20 secs.) to obtain 25 20 troches, each of which weighed 200 mg (36.4 mg of ibuprofen, 18.2 mg of WS 23). 3. Working example 3 1.0g of ibuprofen and 0.5 g of WS-3(commercialized cooling compound; 30 chclohexanecarboxamide, N-ethyl-5-methyl-2-(1-methylethyl); from Millennium Specialty Chemicals) were dissolved in 2 ml of EtOH, and the resultant solution was added to 4 g of D-sorbitol in a motor. The resultant composition was then kneaded well. Afterwards, the composition was dried at room temperature overnight, 12 WO 2007/055887 PCT/US2006/041024 pulverized by motor and sieved with 0.5mm opening. The resultant particles were then mixed with 0.1g of Mg-st(magnesium stearate) for 10 seconds. The prepared granules were then put into a molder for tabletting (13 mm in diameter, in 1.5-2.0t pressure for 20 secs.),to obtain 20 troches, each of which weighed 200 mg (36.4 mg 5 of ibuprofen, 18.2 mg of WS-3). 4. Working example 4 1.0g of ibuprofen was dissolved in 2 ml of EtOH and 1.0 g of citric acid was dissolved in 1 ml of purified water, respectively. Both solutions were combined and 10 mixed thoroughly using a vortex mixer. The resultant solution was added to 4 g of D-sorbitol in a motor. The resulting composition was then kneaded well. Afterwards, the composition was then dried at 50 0C under reduced pressure for 5 days. The composition was pulverized by a motor, sieved with 0.5 mm opening, then mixed with 0.1g of Mg-st(magnesium stearate) for 10 seconds. The prepared 15 granules were then put into a molder for tabletting (13 mm in diameter, in 1.5-2.Ot pressure for 20 secs.),to obtain 25 troches, each of which weighed 200 mg (33.3 mg of ibuprofen, 33.3 mg of citric acid). 5. Working example 5 20 1.0g of ibuprofen was dissolved in 2 ml of EtOH and 1.0 g of malic acid was dissolved in 1 ml of purified water, respectively. Both solutions were combined and mixed thoroughly using a vortex mixer. The resultant solution was added to 4 g of D-sorbitol in a motor. The resultant composition was then kneaded well. Afterwards, the composition was dried at 50 0C under reduced pressure for 7 days, 25 pulverized by a motor, sieved with 0.5mm opening, then mixed with 0.1g of Mg-st (magnesium stearate) for 10 seconds. The prepared granules were put into a molder for tabletting (13 mm in diameter, in 1.5-2.Ot pressure for 20 secs.)to obtain 25 troches, each of which weighed 200mg (33.3 mg of ibuprofen, 33.3 mg of malic acid). 30 6. Working example 6 1.0g of ibuprofen was dissolved in 2 ml of EtOH and 1.0 g of glutamic acid was dissolved in 1 ml of purified water, respectively. Both solutions were combined 13 WO 2007/055887 PCT/US2006/041024 and mixed thoroughly using a vortex mixer. The resultant solution was added to 4 g of D-sorbitol in a motor. The resultant composition was then kneaded well. Afterwards, the composition was dried at room temperature overnight, pulverized by motor, sieved with 0.5 mm opening, then mixed with 0.1g of Mg-st(magnesium 5 stearate) for 10 seconds. The prepared granules were then put into a molder for tabletting (13 mm in diameter, in 1.5-2.Ot pressure for 20 secs.) to obtain 25 troches, ach of which weighed 200 mg (33.3 mg of ibuprofen, 33.3 mg of glutamic acid). 7. Working example 7 10 1.0g of ibuprofen was dissolved in 2 ml of EtOH and 1.0 g of taurine was dissolved in 1 ml of purified water, respectively. Both solutions were combined and mixed thoroughly using a vortex mixer. The resultant solution was added to 4 g of D-sorbitol in a motor. The resultant composition was then kneaded well. Afterwards, the composition was dried at room temperature overnight, pulverized by 15 motor, sieved with 0.5 mm opening, then mixed with 0.1g of Mg-st(magnesium stearate) for 10 seconds. The prepared granules were put into a molder for tabletting (13 mm in diameter, in 1.5-2.Ot pressure for 20 secs.), to obtain 25 troches, each of which weighed 200 mg (33.3 mg of ibuprofen, 33.3 mg of taurine). 20 8. Working example 8 3.Og of ibuprofen was dissolved in 4 ml of EtOH, and 3.0 g of beta cyclodextrin was kneaded with 2ml of purified water in motor, respectively. The ibuprofen solution was added to the component of beta-cyclodextrin in a motor. The resultant composition was then kneaded well. Afterwards, the composition was 25 dried at room temperature overnight, pulverized by motor, sieved with 0.5 mm opening, then mixed with 0.1g of Mg-st(magnesium stearate) for 10 seconds. The prepared granules were put into a molder for tabletting (13 mm in diameter, in 1.5 2.Ot pressure for 20 secs.), to obtain 60 troches, each of which weighed 80 mg (40 mg of ibuprofen, 40 mg of beta-cyclodextrin). 30 9. Working example 9 (as comparative sample) 1.0g of ibuprofen was dissolved in 2 ml of EtOH and then 1 ml of purified water was added. The resultant solution was added to 4 g of D-sorbitol in a motor. 14 WO 2007/055887 PCT/US2006/041024 The resultant composition was then kneaded well. Afterwards, the composition was dried at 50-60 *C overnight, pulverized by motor, sieved with 0.5 mm opening, then mixed with 0.1g of talc for 10 seconds. The prepared granules were put into a molder for tabletting (13 mm in diameter, in 1.5-2.Ot pressure for 20 secs.),to obtain 5 20 troches, each of which weighed 200 mg (40 mg of ibuprofen). 10. Test example: Effectiveness to reduce the unacceptably irritant sensation of ibuprofen 10 (Method) The unpleasant irritant sensation of ibuprofen is tested with panelists using the ibuprofen troche prepared in the procedures of working example 1-9 as a comparison sample. (Result) As shown in Table 1, it is confirmed that the unpleasant irritant sensation of 15 ibuprofen is reduced by adding the following ingredients, I-menthol, WS-23, WS-3, citric acid, malic acid, glutamic acid, taurine and beta-cyclodextrin. Table 1 Ingredient/working Degree of Irritation* example No. -2 -1 0 +1 +2 I-Menthol/1 1 1 WS-23/2 3 WS-3/3 2 Citric acid/4 1 1 Malic acid/5 1 1 Glutamic acid/6 2 Taurine/7 2 Beta cyclodextrin/8 1 No ingredient/9 (comparison sample) 2 * +2: strong irritation, +1: medium irritation, 0: a little irritation, 20 -1: little irritation, -2: no irritation 15 WO 2007/055887 PCT/US2006/041024 It is observed that the subject ibuprofen troche (5mg and 10mg) showed efficacy of pain relief with 8 volunteers, and 10 mg troche showed better result than 5mg, similar to the results observed with another formulation in Hei.4-26618. 5 As demonstrated above, a solid dosage formulation containing ibuprofen, such as a lozenge, troche or gum, which further includes the ingredients listed above, can alleviate inflammation or pain in the laryngopharynx by its direct action to the oral mucous membrane and the pharyngeal mucous membrane. The content of ibuprofen per unit is lower than that of the OTC oral preparations and the 10 preparation is safe with no adverse reactions confirmed. 11. Test example: Effectiveness of ibuprofen troche to relieve sore throat, as well as to irritant sensation masking 15 (Method) The effectiveness to relieve sore throat was evaluated with volunteers using ibuprofen troches prepared as follows: 1.0g of ibuprofen was dissolved in 2 ml of EtOH, and 1.0g of beta cyclodextrin was kneaded with 0.5 ml of purified water in motor, respectively. The 20 ibuprofen solution was added to the component of beta-cyclodextrin in a motor. The resultant composition was then kneaded well. Afterwards, the composition was dried at room temperature overnight, pulverized by motor, sieved 0.5 mm opening to produce Ibuprofen/beta-cyclodextrin granules. 0.5g of I-menthol was dissolved in 2 ml of EtOH, and 2.5g of D-sorbitol was 25 kneaded with 1 ml of purified water in motor, respectively. The I-menthol solution was added to the component of D-sorbitol in a motor. The resultant composition was then kneaded well. Afterwards, the composition was dried at room temperature overnight, pulverized by motor, sieved 0.5 mm opening to produce I-menthol/D sorbitol granules. 30 Then, the ibuprofen/beta-cyclodextrin granules and I-menthol/D-sorbitol granules were mixed well 0.1g of Mg-st (magnesium stearate) for 10 seconds. The prepared granules were put into a molder for tabletting (13 mm in diameter, in 1.5 16 WO 2007/055887 PCT/US2006/041024 2.0 t pressure for 20 secs.), to obtain 25 troches, each of which weighed 200 mg(40 mg of ibuprofen, 40 mg of beta-cyclodextrin, 20 mg of I-menthol). (Result) 5 As shown in Table 2, it was confirmed that the ibuprofen troches worked well to relieve sore throat, and irritant sensation of ibuprofen was reduced by applying current formulations. Table 2 effectiveness volunteer age gender to irritant remarks sore throat sensation* 1 38 F not tested -2 Working example 1 was used. She got also clearing nasal passage. 2 48 F imrove -2 But she preferred peppermint flavour to I 2 48 F improved -2was too strong for her. She also preferred peppermint flavor to I 3 36 F improved -2 menthol. 4 27 F improved 0 She had no more sore throat next day. Peppermint was used instead of I 5 27 F not tested -2 menthol in working example 10. Peppermint was used instead of I 6 55 F not tested -1 menthol in working example 10. Peppermint was used instead of I 7 56 M not tested -2 menthol ___________in working example 10. Peppermint was used instead of I 8 38 F not tested -1 menthol in working example 10. B Peppermint was used instead of I menthol in working example 10. 9 60 F improved -2 The amount of main component was different from example 10 as follows; 20mg of ibuprofen, 30mg of beta P cyclodextrin, 1mg of peppermint oil *+2: strong irritation, +1: medium irritation, 0: a little irritation, -1: little irritation, -2: no irritation 10 It is evident from the above results and discussion that the subject invention provides important new oral ibuprofen formulations that are organoleptically acceptable and economical to produce. As such, the subject invention represents a significant contribution to the art. 17 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from 5 the spirit or scope of the appended claims. Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, 10 all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as 15 well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the 20 exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims. Throughout this specification and the claims, unless the context requires otherwise, the word "comprise" and its variations, such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or 25 group of integers but not the exclusion of any other integer or step or group of integers or steps. The reference to any prior art in this specification is not, and should not be taken as an acknowledgement or any form of suggestion that prior art forms part of the common general knowledge in Australia. 18

Claims (26)

1. An organoleptically acceptable solid oral dosage formulation of ibuprofen, said formulation comprising: 5 ibuprofen; and a masking component; wherein said formulation does not include a cyclodextrin in an amount that is two or more times the amount of ibuprofen in said formulation and said solid dosage formulation is formulated to be maintained in a subject's mouth for duration of 10 ibuprofen delivery.
2. The formulation according to Claim 1, wherein said masking component includes a cooling agent.
3. The formulation according to Claim 1, wherein said masking component includes an organic acid. 15
4. The formulation according to Claim 1, wherein said masking component includes a cyclodextrin.
5. The formulation according to Claim 1, wherein said masking component 20 includes two or more of a cooling agent and an organic acid.
6. The formulation according to Claim 5, wherein said masking component includes a cooling agent, an organic acid and a cyclodextrin. 25
7. An organoleptically acceptable solid oral dosage formulation of ibuprofen, said formulation comprising: (a) ibuprofen; and (b) a masking component comprising at least one of: (i) a cooling agent; and 30 (ii) an organic acid; wherein said formulation does not include a cyclodextrin in an amount that is 19 two or more times the amount of ibuprofen in said formulation and said solid dosage formulation is formulated to be maintained in a subject's mouth for duration of ibuprofen delivery. 5
8. The formulation according to Claim 7, wherein said masking component includes both said cooling agent and said organic acid.
9. The formulation according to Claim 7, wherein said formulation includes a cyclodextrin. 10
10. The formulation according to Claim 2 or 7, wherein said cooling agent is chosen from I-menthol, dl-menthol, WS-23 (N,2,3-trimethyl-2-isopropyl butamide), WS-3 (cyclohexane carboxamide, N-ethyl-5-methyl-2-(1-methylethyl), peppermint oil and spearmint oil. 15
11. The formulation according to Claim 3 or 7, wherein said organic acid is chosen from asparaginic acid, citric acid, malic acid, glutamic acid, taurine tartaric acid and succinic acid. 20
12. The formulation according to Claim 1 or 7, wherein said solid dosage formulation is a lozenge, troche, tablet or gum.
13. A method of treating a subject for sore throat or hoarse voice, said method comprising: 25 placing an organoleptically acceptable solid oral dosage formulation of ibuprofen and a masking component in said subject's mouth; and maintaining said formulation in said subject's mouth for the duration of ibuprofen delivery; to treat said subject for sore throat or hoarse voice. 30 20
14. The method according to Claim 13, wherein said method is a method of treating said subject for sore throat.
15. A method of making a non-irritating oral solid dosage formulation of 5 ibuprofen, said method comprising: (a) producing an intermediate composition comprising: ibuprofen; and a masking component; wherein said intermediate composition does not include a cyclodextrin 10 in an amount that is two or more times the amount of ibuprofen in said formulation; and (b) preparing a solid oral dosage formulation from said intermediate composition, wherein said solid dosage formulation is formulated to be maintained in a subject's mouth for duration of ibuprofen delivery. 15
16. The method according to Claim 15, wherein said masking component includes at least one of a cooling agent and an organic acid.
17. The method according to Claim 15, wherein said solid dosage formulation is 20 a lozenge, troche, tablet or gum.
18. The formulation according to Claim 1 or 7, wherein said ibuprofen is present in an amount ranging from about 50 mg to about 200 mg. 25
19. The formulation according to Claim 2 or 7, wherein the ratio of the amount of said cooling agent to ibuprofen present in the formulation ranges from about 0.25 to about 2.
20. The method according to Claim 13, wherein said formulation does not 30 include a cyclodextrin in an amount that is two or more times the amount of ibuprofen in said formulation. 21
21. The formulation according to Claim 1 or 7, said formulation consisting essentially of: ibuprofen; and a masking component; and 5 a diluent; and a lubricant.
22. The formulation according to Claim 1 or 7, said formulation consisting essentially of: 10 ibuprofen; and two or more masking components; and a diluent; and a lubricant. 15
23. The formulation according to Claim 1 or 7, wherein said formulation does not include a cyclodextrin and is a lozenge or troche.
24. An organoleptically acceptable solid oral dosage formulation of ibuprofen substantially as herein disclosed with reference to any one or more of the examples, 20 excluding comparative examples.
25. A method of orally administering ibuprofen to a subject in need thereof substantially as herein disclosed with reference to any one or more of the examples, excluding comparative examples. 25
26. A method of making a non-irritating oral solid dosage formulation of ibuprofen substantially as herein disclosed with reference to any one or more of the examples, excluding comparative examples. 22
AU2006312119A 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same Ceased AU2006312119B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010202050A AU2010202050A1 (en) 2005-11-02 2010-05-20 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73312705P 2005-11-02 2005-11-02
US60/733,127 2005-11-02
US81041706P 2006-06-01 2006-06-01
US60/810,417 2006-06-01
PCT/US2006/041024 WO2007055887A1 (en) 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010202050A Division AU2010202050A1 (en) 2005-11-02 2010-05-20 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Publications (2)

Publication Number Publication Date
AU2006312119A1 AU2006312119A1 (en) 2007-05-18
AU2006312119B2 true AU2006312119B2 (en) 2010-04-29

Family

ID=38023574

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006312119A Ceased AU2006312119B2 (en) 2005-11-02 2006-10-17 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
AU2010202050A Abandoned AU2010202050A1 (en) 2005-11-02 2010-05-20 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010202050A Abandoned AU2010202050A1 (en) 2005-11-02 2010-05-20 Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Country Status (12)

Country Link
US (1) US20070098789A1 (en)
EP (1) EP1942877A4 (en)
JP (2) JP2009514857A (en)
KR (1) KR20080034166A (en)
CN (1) CN103622926A (en)
AR (1) AR056749A1 (en)
AU (2) AU2006312119B2 (en)
BR (1) BRPI0618273A2 (en)
CA (1) CA2620219A1 (en)
RU (2) RU2008116871A (en)
TW (1) TW200733954A (en)
WO (1) WO2007055887A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620219A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
BRPI0718428A2 (en) * 2006-10-25 2013-11-12 Mcneil Ppc Inc IBUPROPHEN COMPOSITION
JP5821247B2 (en) * 2010-04-07 2015-11-24 大正製薬株式会社 Method for inhibiting sublimation of ibuprofen
CA2833105C (en) * 2011-04-11 2019-04-23 Ayanda Group As Oral pharmaceutical dispersion compositions
CN102258490B (en) * 2011-07-01 2012-10-03 中美天津史克制药有限公司 Ibuprofen chewable tablet
US9914968B2 (en) 2012-09-26 2018-03-13 Cepheid Honeycomb tube
FR2997856B1 (en) * 2012-11-14 2015-04-24 Pf Medicament DRUG PASTILLE BASED ON IBUPROFEN SODIUM DIHYDRATE
CN103690474B (en) * 2013-12-04 2015-09-30 郑州大明药物科技有限公司 The preparation method of Ibuprofen cream

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2219585A (en) * 1988-06-09 1989-12-13 Reckitt & Colmann Prod Ltd Cyclodextrin/ibuprofen complexes
JPH0426618A (en) * 1990-05-21 1992-01-29 Japan Tobacco Inc Troche

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
CH677606A5 (en) * 1988-07-12 1991-06-14 Aesculapius Pharma Sa
US4916161A (en) * 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5055461A (en) * 1989-02-15 1991-10-08 Richardson-Vicks Inc. Anesthetic oral compositions and methods of use
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
ATE216577T1 (en) * 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd QUICK DISSOLVABLE TABLET AND PRODUCTION THEREOF
GB9207990D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition
EP0695175A1 (en) * 1993-04-30 1996-02-07 The Procter & Gamble Company Coated pharmaceutical compositions
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5616344A (en) * 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5560913A (en) * 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
TW442287B (en) * 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
ES2164849T3 (en) * 1995-10-17 2002-03-01 Reckitt Benckiser Healthcare WATERPROOF SOLUTIONS WITH MASKED FLAVOR CONTAINING IBUPROFEN AND MENTOL.
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5912007A (en) * 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
WO1998002182A1 (en) * 1996-07-12 1998-01-22 Novartis Consumer Health S.A. Oral pharmaceutical combinations of nsaids with terpenoids
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
WO1999055320A1 (en) * 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Oral formulation comprising biguanide and an organic acid
US20020110581A1 (en) * 1999-04-06 2002-08-15 Ream Ronald L. Over-coated product including consumable center and medicament
US20050042271A1 (en) * 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
ES2171110B1 (en) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas PHARMACEUTICAL COMPOSITION BASED ON IBUPROFEN AND PROCEDURE FOR PREPARATION.
WO2003009834A1 (en) * 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
CA2419147C (en) * 2000-08-25 2008-10-07 Kowa Company, Ltd. Fill liquid composition for ibuprofen capsule and capsule preparation
IT1319229B1 (en) * 2000-10-20 2003-09-26 Savio Macchine Tessili Spa PERFECTED ROLL-HOLDER DEVICE FOR WINDING OF YARN WITH REGULATED CONPRESSION, PARTICULARLY FOR DOUBLE TORSION TWISTING.
EP1391201A4 (en) * 2001-05-25 2004-06-30 Ssp Co Ltd Medicinal compositions
US8859028B2 (en) * 2002-06-14 2014-10-14 Cereal Ingredients, Inc. Coated food particle and method for making a swirl
GB0217382D0 (en) * 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
US20040071852A1 (en) * 2002-10-09 2004-04-15 Yael Vodovotz Compositions and processes for making high soy protein-containing bakery products
DK1553848T3 (en) * 2002-10-11 2008-01-21 Novozymes As Process for preparing a heat treated product
JP4815867B2 (en) * 2004-05-11 2011-11-16 大正製薬株式会社 Stabilized solid formulation
US20060263475A1 (en) * 2004-08-25 2006-11-23 Cadbury Adams Usa, Llc. Center-filled chewing gum composition
JP2008525420A (en) * 2004-12-23 2008-07-17 マクニール−ピーピーシー・インコーポレーテツド Mouth disintegrating medicinal composition with sensory trigger
CA2620219A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2219585A (en) * 1988-06-09 1989-12-13 Reckitt & Colmann Prod Ltd Cyclodextrin/ibuprofen complexes
JPH0426618A (en) * 1990-05-21 1992-01-29 Japan Tobacco Inc Troche

Also Published As

Publication number Publication date
BRPI0618273A2 (en) 2011-08-23
RU2012138581A (en) 2014-03-20
AU2010202050A1 (en) 2010-06-10
AU2006312119A1 (en) 2007-05-18
CA2620219A1 (en) 2007-05-18
WO2007055887A1 (en) 2007-05-18
CN103622926A (en) 2014-03-12
RU2008116871A (en) 2009-12-10
US20070098789A1 (en) 2007-05-03
EP1942877A1 (en) 2008-07-16
KR20080034166A (en) 2008-04-18
AR056749A1 (en) 2007-10-24
EP1942877A4 (en) 2011-09-14
JP2009514857A (en) 2009-04-09
JP2012255018A (en) 2012-12-27
TW200733954A (en) 2007-09-16

Similar Documents

Publication Publication Date Title
AU2006312119B2 (en) Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
EP2512446B1 (en) Composition of dexibuprofen transdermal hydrogel
US20090238905A1 (en) Inflammation reducing action of synergistic mixtures of bisabolol and ginger extracts
JP2010270019A (en) Solid internal medicine composition
JP2007530688A (en) Composition with reduced hepatotoxicity
JP5360368B2 (en) Amino acid preparation for oral use with improved dosage
US10028967B2 (en) Medicament
DK2833880T3 (en) Oral solid dosage composition with ibuprofen comprising a methacrylic acid copolymer
JP5577168B2 (en) Oral pharmaceutical composition
JP2001010977A (en) Composition for oral administration
CA2547194C (en) Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability
CN101262854A (en) Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
FR2660195A1 (en) PHARMACEUTICAL CHEWING, ANTI-INFLAMMATORY AND / OR ANALGESIC COMPOSITION.
KR102545748B1 (en) Spray formulation containing flurbiprofen and a process for the preparation thereof
ES2694710T3 (en) Tablets comprising an agent that masks the taste
JPS62270523A (en) Non-stimulant suprofen solution
JP2004331660A5 (en)
TW200826923A (en) A composition for the treatment and prevention of peptic ulcer
AU2018376176A1 (en) Stable liquid composition of ketoprofen, salts and enantiomers thereof
AU2006252204B2 (en) Prevention of Flap Necrosis in Plastic Surgery
TR201620498A2 (en) PHARMACEUTICAL COMPOSITION CONTAINING ACETYLSISTE AND PARACETAMOL
Gulagannavar Design and evaluation of orodispersible taste masked valdecoxib tablets
JP2005120063A (en) Ambroxol for treating inflammation at pharynx
MXPA03009443A (en) Ambroxol for the treatment of inflammation in the pharynx.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired